elobixibat

 

Topic mentions per year

Topic mentions per year

2013-2017
02420132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Elobixibat is an oral treatment candidate for chronic constipation with a novel mechanism of action via inhibition of the ileal… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Review
2016
Review
2016
Irritable bowel syndrome (IBS) is a prevalent functional gastrointestinal disorder, which represents a major cost to healthcare… (More)
Is this relevant?
2015
2015
BACKGROUND Elobixibat is a minimally absorbed ileal bile acid (BA) transporter (IBAT) inhibitor in development against chronic… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Review
2015
Review
2015
Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are two common functional… (More)
Is this relevant?
Review
2015
Review
2015
INTRODUCTION Constipation predominant irritable bowel syndrome (IBS-C) is a common disorder and accounts for a large number of… (More)
Is this relevant?
Review
2014
Review
2014
Chronic idiopathic constipation is highly prevalent among adults. Bile acids (BAs) and the enterohepatic BA circulation modulate… (More)
Is this relevant?
Review
2014
Review
2014
INTRODUCTION A number of new medications were recently demonstrated to be more effective than placebo in treating chronic… (More)
Is this relevant?
Review
2014
Review
2014
BACKGROUND Bile acids are increasingly implicated in the pathogenesis of functional GI disorders. New mechanisms have recently… (More)
Is this relevant?
Review
2014
Review
2014
INTRODUCTION Chronic constipation (CC) is a common gastrointestinal (GI) motility disorder that significantly impairs the quality… (More)
  • table 1
  • table 1
  • table 3
Is this relevant?
Review
2013
Review
2013
INTRODUCTION Elobixibat (formerly A3309) is a first-in-class ileal bile acid transporter (IBAT) inhibitor for treatment of… (More)
Is this relevant?